Eli Lilly Drug Reduces Diabetes Risk

Weight Loss Drug Demand Drives Eli Lilly Sales

CNBC on MSN · 1d

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Barron's on MSN · 17d

Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The big pharma companies Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,

Reuters on MSN · 1d

Lilly reassures investors that weight-loss drug demand is strong, shares rise

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs. Lilly said o

FierceBiotech1d

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

10don MSN

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

KSL29d

Eli Lilly's obesity drug gets Medicare coverage for sleep apnea

WASHINGTON — Eli Lilly's obesity ... rival Novo Nordisk's obesity drug Wegovy also gained Medicare coverage to reduce the risk of heart attacks and strokes. Lilly and Novo are testing ...

biznews.com17d

🔒 FT: Weight-loss drugs reduce risk of Alzheimer’s, large study shows

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.

FiercePharma17d

Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results